Ariad Directors Beat Investor Suit Over Failed Leukemia Drug
The directors of Ariad Pharmaceuticals Inc. shut down a shareholder derivative suit alleging Ariad's leadership hid problems with a leukemia drug it eventually pulled from the market, sending the company to...To view the full article, register now.
Already a subscriber? Click here to view full article